162 related articles for article (PubMed ID: 31300605)
1. Acquired C1-inhibitor deficiency presenting with nephrotic syndrome.
Willows J; Wood K; Bourne H; Sayer JA
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300605
[TBL] [Abstract][Full Text] [Related]
2. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib.
Sekiguchi Y; Nishimura Y; Kanda H; Kawamura M; Kobayashi K; Kobayashi H
Intern Med; 2022 Aug; 61(16):2503-2508. PubMed ID: 35110483
[TBL] [Abstract][Full Text] [Related]
3. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
4. [Recurrent isolated angioedema as a result of acquired C1 inhibitor deficiency].
Bosma J; Bijl JM; Siegert CE; Vasmel WL
Ned Tijdschr Geneeskd; 2014; 158():A7184. PubMed ID: 24666532
[TBL] [Abstract][Full Text] [Related]
5. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
6. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K; Poulain S; Willems L; Merabet F; Le Calloch R; Eveillard JR; Herbaux C; Roos-Weil D; Chaoui D; Roussel X; Tricot S; Dupuis J; Dartigeas C; Bareau B; Bene MC; Baugier de Materre A; Leblond V
Br J Haematol; 2019 Jul; 186(1):146-149. PubMed ID: 30548257
[No Abstract] [Full Text] [Related]
8. Renal involvement in Waldenström's macroglobulinemia: case report and review of literature.
Salviani C; Guido G; Serriello I; Giannakakis K; Rocca AR
Ren Fail; 2014 Feb; 36(1):114-8. PubMed ID: 24059636
[TBL] [Abstract][Full Text] [Related]
9. Cases of acquired C1 inhibitor deficiency treated with rituximab.
Doshi A; Tse K; Riedl M; Zuraw B; Christiansen S
J Allergy Clin Immunol Pract; 2016; 4(5):987-8. PubMed ID: 27130715
[No Abstract] [Full Text] [Related]
10. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship.
Castelli R; Zanichelli A; Cicardi M; Cugno M
Crit Rev Oncol Hematol; 2013 Sep; 87(3):323-32. PubMed ID: 23490322
[TBL] [Abstract][Full Text] [Related]
11. Acquired Angioedema due to C1 Inhibitor Deficiency Preceding Splenic Marginal Zone Lymphoma: Further Insights from Clinical Practice.
Ferriani MPL; Trevisan-Neto O; Costa JS; Melo JML; Moreno AS; Dias MM; Garibaldi PMM; Pereira GC; Chahud F; Traina F; Arruda LK
Int Arch Allergy Immunol; 2020; 181(12):941-946. PubMed ID: 32894844
[TBL] [Abstract][Full Text] [Related]
12. [Acquired C1 esterase inhibitor deficiency via bradykinin-mediated angioedema: Four cases].
Jacquin-Porretaz C; Castelain F; Daguindau E; Seilles E; Nardin C; Aubin F; Pelletier F
Ann Dermatol Venereol; 2018 Oct; 145(10):598-602. PubMed ID: 29673745
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
14. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.
Bork K; Staubach-Renz P; Hardt J
Orphanet J Rare Dis; 2019 Mar; 14(1):65. PubMed ID: 30866985
[TBL] [Abstract][Full Text] [Related]
15. [Kidney involvement in Waldenström's disease - case report].
Fomasi L; Foini P; Marchi G; Ghiringhelli P; Molteni A; Ungari M; Fisogni S; Malberti F
G Ital Nefrol; 2021 Feb; 38(1):. PubMed ID: 33599424
[TBL] [Abstract][Full Text] [Related]
16. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2019 Feb; 94(2):266-276. PubMed ID: 30328142
[TBL] [Abstract][Full Text] [Related]
17. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
19. The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity.
Wu MA; Castelli R
Clin Chem Lab Med; 2016 Feb; 54(2):207-14. PubMed ID: 26068904
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Angioedema: Occurrence, Features, and Concomitant Diseases in an Italian Single-Center Study.
Triggianese P; Guarino MD; Pellicano C; Borzi M; Greco E; Modica S; De Carolis C; Perricone R
Int Arch Allergy Immunol; 2017; 172(1):55-63. PubMed ID: 28222436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
